NCT04287621

Registry of Asthma Patients Initiating DUPIXENT®

Registry of Asthma Patients Initiating DUPIXENT® (RAPID)

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 718 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: * Patient demographics (eg, gender, age, and race) * Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are: * To characterize real-world use patterns of DUPIXENT® for asthma * To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting * To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® * To collect long-term safety data on study participants in the real-world setting

Detailed description

3-year registry of real-world use of DUPIXENT® for asthma in patients age 12 and over

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	DUPIXENT®	There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.

Timeline

• Start date: 2020-03-02
• Primary completion: 2026-04-27
• Completion: 2026-04-27
• First posted: 2020-02-27
• Last updated: 2026-02-27

Locations

128 sites across 10 countries: United States, Canada, Denmark, France, Italy, Japan, Puerto Rico, Spain, Sweden, United Kingdom

Regulatory

• FDA-regulated drug study